MOTS-c Dosage: Dosing, and What It Means for Lean Mass

A vendor page lists a MOTS-c dosage beside a price, in milligrams, to one decimal place. The precision reads like a finding. It is not one. No human trial has published a dose response for this peptide, and no study in any species has compared doses against a body composition outcome, so the figure on that page came from somewhere other than research.

This article is about where. Not what to take, which nobody can responsibly tell you, but why the numbers exist at all and what they are worth.

Precision without a source

Numbers acquire authority from their format. A range written as a range, with units, sitting under a product photograph, looks like it was extracted from a paper. Readers rarely ask which paper, and vendors are not required to say.

For this compound the honest answer is that the retail figures are conventions. They stabilised because sellers copied each other, because they divide neatly into a standard vial, and because a plausible looking number sells better than an admission of ignorance. Once enough pages agree, agreement itself starts functioning as evidence, and a figure that began as packaging arithmetic ends up quoted as a protocol.

Where MOTS-c dosage numbers actually come from

Every row above is either not about humans or not about evidence. That is the whole situation, laid out.

Why a mouse dose does not convert

The scaling problem gets waved away with a conversion factor, and the factor is real, but it is an estimate for planning first in human studies rather than a translation table.

Species differ in how quickly they clear a peptide, in where it distributes, in metabolic rate per unit mass, and in the density of whatever it acts on. A mouse metabolises at a rate no human matches. Two compounds scaled by the same rule can land in completely different places in a person, which is precisely why regulators require dose finding studies in humans instead of accepting arithmetic.

There is a second issue specific to this molecule. Rodent metabolic experiments give a compound to sedentary, genetically similar animals on a controlled diet, and measure glucose handling or body weight. A trained forty five year old on a self selected diet differs on every one of those axes. Even a correct milligram conversion would be answering a question asked in a different setting.

Dose finding is a study design, not a calculation

In drug development a dose is not derived, it is discovered. Early human studies escalate exposure in small groups under monitoring, measuring what the body does with the compound and what happens as the amount rises. Only afterwards does a later trial test whether the selected dose produces the intended effect.

That sequence exists because the alternative does not work. Clearance, distribution, target density and the shape of the response curve differ enough between species that arithmetic on body weight regularly lands in the wrong place, sometimes far enough to matter.

For this peptide, none of that process exists. There is no human pharmacokinetic dataset available to reason from, no published escalation study, and nothing under way that would produce either.

Which leaves anyone calculating from a rodent paper doing, unsupervised and with an unverified product, the part of drug development normally done in a clinic with monitoring.

The trial number that gets attached to the dose

A figure quoted with a trial number behind it reads very differently from one quoted alone, which is why the number travels further than the dose does. For this peptide the number is NCT07505745, and it is worth understanding before it is used to justify anything measured in milligrams.

The record exists. It is listed as Phase 2, it names an enrolment figure, it describes adults with prediabetes and overweight or obesity, its stated endpoint is insulin sensitivity, and its status reads recruiting. Anyone confirming that the identifier resolves gets a clean result, and that is where checking usually stops.

The sponsor field is where it falls over. The record shares a lead sponsor with seven others submitted to the same registry between February and April 2026, all listed as recruiting, all naming a single hospital site, and covering between them compounds that match a retail catalogue rather than a research programme, from tanning and healing peptides to two weight loss drugs. One of the seven states in its own brief summary that it is a fictional example of a registry style record. The sponsor has no drug application on file with the FDA and nothing published under its name.

So there is no registered human trial of this peptide, and there is no trial dose. There is a registry entry with a dose written into it, which is a number on a form rather than a quantity that was administered to anybody, monitored, or compared against a different one.

That is worse than it sounds for anyone doing arithmetic. A dose in a genuine protocol is at least a considered choice made by investigators with something to lose if it is wrong, reviewed before enrolment and answerable to the people who take it. A dose in an unverified record carries none of that. It has the format of evidence and none of the provenance, which puts it in the same category as the vendor figures at the top of this article while looking considerably more official.

The general point outlives this compound. An identifier tells you a registration was accepted. It does not tell you a study happened, and it never tells you a dose was validated. The lead sponsor and the brief summary are the two fields that separate one from the other, and both take seconds to read.

Every other registry hit for this compound is an artefact of keyword search. Registry searches match text anywhere in a record, and the other hits returned for this peptide involve anaesthesia, vestibular implants and exercise in cancer and dialysis populations. None of them studies MOTS-c.

The lean mass question hiding underneath

People search for a dose because they have already decided the compound does something, and on this site the assumed something is usually body composition. That assumption deserves its own answer.

No study in any organism has measured muscle mass, cross sectional area or strength after MOTS-c administration. The peptide has no described action on the myostatin pathway, on satellite cells or on muscle protein synthesis. There is no dose for lean mass because there is no established effect on lean mass to dose for.

Two ideas get merged at this point and are worth separating. Partitioning describes where energy goes once it arrives: toward oxidation, toward glycogen, toward fat storage, toward repairing tissue that was trained. Growth describes net addition of contractile protein, which requires a training stimulus, adequate substrate and time. A compound acting on the first does not thereby act on the second, and for this peptide even the first has been reported only in mice.

The legitimate version of the interest is indirect and metabolic. Insulin sensitivity in humans tends to decline with age and with fat gain, and as it declines, holding lean tissue through a deficit gets harder on the same effort. A peptide reported to improve glucose handling in mice is aimed at a variable that genuinely matters over decades. Aimed at is not the same as demonstrated in, and improved partitioning is not growth.

Concentration is not the only unknown

Suppose a person settled on a figure. They would still not know what they administered.

MOTS-c holds no marketing authorisation anywhere. It is sold as a research chemical, so identity, purity and quantity rest on the seller's word. A vial labelled with a quantity may hold less, may hold degraded material, and may contain related impurities from synthesis. Reconstitution adds another layer of uncertainty, and peptides in solution degrade at rates that depend on storage.

The result is that a carefully calculated dose is calculated from a number that was never verified. Precision applied to an unverified input produces confidence, not accuracy, and confidence is the more dangerous of the two.

A third party certificate of analysis narrows this a little and does not close it. A certificate describes the batch that was tested, at the time it was tested, which is not necessarily the vial that arrived.

Questions people ask at this point